Trace elements in bipolar disorder

Journal of Trace Elements in Medicine and Biology

Volumn 25, Issue SUPPL. 1, 2011, Pages

  González Estecha, Montserrat ^a   Trasobares, Elena M ^a   Tajima, Kazuhiro ^a   Cano, Sara ^a   Fernández, Cristina ^a   López, José Luis ^b   Unzeta, Belén ^a   Arroyo, Manuel ^a   Fuentenebro, Filiberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Bipolar disorder; Cadmium; Copper; Depression; Lead; Mania; Thallium; Zinc

Indexed keywords

CADMIUM; COPPER; LEAD; THALLIUM; TRACE ELEMENT; ZINC;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIPOLAR DISORDER; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SMOKING; TRACE METAL BLOOD LEVEL; URINALYSIS;

BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; SMOKING; SUBSTANCE-RELATED DISORDERS; TRACE ELEMENTS;

EID: 79952698094     PISSN: 0946672X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtemb.2010.10.015     Document Type: Article

References (60)

1. Mustak M.S., Rao T.S., Shanmugavelu P., Sundar N.M., Menon R.B., Rao R.V., et al. Assessment of serum macro and trace element homeostasis and the complexity of inter-element relations in bipolar mood disorders. Clin Chim Acta 2008, 394:47-53.
2. ATSDR. Toxicological profile for lead. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2007. Available from: (cited 01.01.08). http://www.atsdr.cdc.gov/toxprofiles/tp13.html.
3. ATSDR. Toxicological profile for cadmium. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2008. Available from: (cited 29.11.08). http://www.atsdr.cdc.gov/toxprofiles/tp13.html.
4. Sullivan J.B. Thallium. Clinical environmental health and toxic exposures 2001, 954-958. Lippincott Williams & Wilkins, Philadelphia. J.B. Sullivan, G.R. Krieger (Eds.).
5. Linter C.M. Neuropsychiatric aspects of trace elements. Br J Hosp Med 1985, 34:361-365.
6. Srinivasan D.P., Marr S., Waring R.A., Birch N.J. Magnesium, zinc and copper in acute psychiatric patients. Magnesium-B 1982, 4:45-48.
7. Naylor G.J., Smith A.H.W., Bryce-Smith D., et al. Trace elements in manic depressive psychosis. J Affect Disord 1985, 8:131-136.
8. Mc Loughlin I.J., Hodge J.S. Zinc in depressive disorder. Acta Psychiatr Scand 1990, 82:451-453.
9. Maes M., D'Haese P.C., Scharpé S., D'Hondt P., Cosyns P., De Broe M.E. Hypozincemia in depression. J Affect Disord 1994, 31:135-140.
10. Narang R.L., Gupta K.R., Narang A.P., Singh R. Levels of copper and zinc in depression. Indian J Physiol Pharmacol 1991, 35:272-274.
11. Stanley P.C., Wakwe V.C. Toxic trace metals in the mentally ill patients. Niger Postgrad Med J 2002, 9:199-204.
12. Nowak G., Szewczyk B. Mechanisms contributing to antidepressant zinc actions. Pol J Pharmacol 2002, 54:587-592.
13. Szewczyk B., Poleszak E., Sowa-Kucma M., Siwek M., Dudek D., Ryszewska-Pokrasniewicz B., et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 2008, 60:588-599.
14. Nowak G., Szewczyk B., Pilc A. Zinc and depression. An update. Pharmacol Rep 2005, 57:713-718.
15. Siwek M., Dudek D., Paul I.A., Sowa-Kucma M., Zieba A., Popik P., et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 2009, 118:187-195.
16. Levenson C.W. Zinc: the new antidepressant?. Nutr Rev 2006, 64:39-42.
17. Schlegel-Zawadzka M., Nowak G. Alterations in serum and brain trace element levels after antidepressant treatment. Part II. Copper. Biol Trace Element Res 2000, 73:37-45.
18. Machado A.C., Deguti M.M., Caixeta L., Spitz M., Lucato L.T., Reis E. Mania as the first manifestation of Wilson's disease. Bipolar Disord 2008, 10:447-450.
19. Nowak G., Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment. Part I. Zinc. Biol Trace Element Res 1999, 67:85-92.
20. Maes M., Vandoolaeghe E., Neels H., Demedts P., Wauters A., Meltzer H.Y., et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997, 42:349-358.
21. González-Estecha M., Trasobares E., Cano S., Oliván P., Fuentes M., Fernández C., et al. Blood lead and cadmium levels and sources of exposure. PESA Study, 2008. Rev Lab Clin 2009, 2:115-123.
22. Rhodes D., Spiro A., Aro A., Hu H. Relationship of bone and blood lead levels to psychiatric symptoms: the Normative Aging Study. J Occup Environ Med 2003, 45:1144-1151.
23. Bouchard M.F., Bellinger D.C., Weuve J., Matthews-Bellinger J., Gilman S.E., Wright R.O., et al. Blood lead levels and major depressive disorder, panic disorder, and generalized anxiety disorder in US young adults. Arch Gen Psychiatry 2009, 66:1313-1319.
24. Menke A., Muntner P., Silbergeld E.K., Platz E.A., Guallar E. Cadmium levels in urine and mortality among US adults. Environ Health Perspect 2009, 117:190-196.
25. CLSI Control of preanalytical variation in trace element determinations; approved guideline. CLSI document C38-A (ISBN 1-56238-332-9) 1997, CLSI, Pennsylvania, USA.
26. Centers for Disease Control and Prevention (CDC). Third national report on human exposure to environmental chemicals. Atlanta: CDC; 2005. Available from: (cited 01.01.08). http://www.cdc.gov/exposurereport/report.html.
27. Budic B., Klemenc S. Determination of trace elements in heroin by inductively coupled plasma atomic emission spectrometry using ultrasonic nebulization. Spectrochim Acta Part B 2000, 55:681-688.
28. Violante N., Quaglia M.G., Lopez A., Caroli S. Characterization of cocaine and heroin samples as a function of their trace element content: an analytical pilot study. Microchem J 1992, 45:79-89.
29. Bora T. Levels of trace and major elements in illicit heroin. J Forensic Sci 2002, 47:959-963.
30. Zhang Z.Y., Yang J.H., Ouyang H., Li Z.J., Chai Z.F., Zhu J., et al. Study of trace impurities in heroin by neutron activation analysis. J Radioanal Nucl Chem 2004, 262:295-297.
31. Cassidy F., Ahearn E.P., Carroll B.J. Substance abuse in bipolar disorder. Bipolar Disord 2001, 3:181-188.
32. Salloum I.M., Thase M.E. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000, 2:269-280.
33. Brockhaus A., Dolgner R., Ewers U., Krämer U., Soddemann H., Wiegand H. Intake and health effects of thallium among a population living in the vicinity of a cement plant emitting thallium containing dust. Int Arch Occup Environ Health 1981, 48:375-389.
34. Insley B.M., Grufferman S., Ayliffe H.E. Thallium poisoning in cocaine abusers. Am J Emerg Med 1986, 4:545-548.
35. Menke A., Muntner P., Batuman V., Silbergeld E.K., Guallar E. Blood lead below 0.48(mol/L (10(g/dL) and mortality among US adults. Circulation 2006, 114:1388-1394.
36. Navas-Acien A., Guallar E., Silbergeld E.K., Rothenberg S.J. Lead exposure and cardiovascular disease - a systematic review. Environ Health Perspect 2007, 115:472-482.
37. Goldstein B.I., Fagiolini A., Houck P., Kupfer D.J. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009, 11:657-662.
38. Lin H.C., Tsai S.Y., Lee H.C. Increased risk of developing stroke among patients with bipolar disorder after an acute mood episode: a six-year follow-up study. J Affect Disord 2007, 100:49-54.
39. Diaz F.J., James D., Botts S., Maw L., Susce M.T., De Leon J. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord 2009, 11:154-165.
40. Heffner J.L., DelBelloMP, Fleck D.E., Anthenelli R.M., Strakowski S.M. Cigarette smoking in the early course of bipolar disorder: association with ages-at-onset of alcohol and marijuana use. Bipolar Disord 2008, 10:838-845.
41. Khalil N., Morrow L.A., Needleman H., Talbott E.O., Wilson J.W., Cauley J.A. Association of cumulative lead and neurocognitive function in an occupational cohort. Neuropsychology 2009, 23:10-19.
42. Fishbein D.H., Todd A.C., Ricketts E.P., Semba R.D. Relationship between lead exposure, cognitive function and drug addiction: pilot study and research agenda. Environ Res 2008, 108:315-319.
43. Shih R.A., Hu H., Weisskop fM.G., Schwartz B.S. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect 2007, 115:483-492.
44. Dittmann S., Seemüller F., Schwarz M.J., Kleindienst N., Stampfer R., Zach J., et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord 2007, 9:63-70.
45. Van Os J., Jones P., Lewis G., Wadsworth M., Murray R. Developmental precursors of affective illness in a general population birth cohort. Arch Gen Psychiatry 1997, 54:625-631.
46. Andreazza A.C., Kauer-Sant'Anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144.
47. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
48. Vaziri N.D. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 2008, 295:454-465.
49. Hsu P.C., Guo Y.L. Antioxidant nutrients and lead toxicity. Toxicology 2002, 180:33-44.
50. Gurer H., Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning?. Free Radic Biol Med 2000, 29:927-945.
51. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64:468-475.
52. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10:607-616.
53. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Center for Pennsylvanians. Bipolar Disord 2005, 7:424-430.
54. Van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008, 10:342-348.
55. McKowen J.W., Frye M.A., Altshuler L.L., Gitlin M.J. Patterns of alcohol consumption in bipolar patients comorbid for alcohol abuse or dependence. Bipolar Disord 2005, 7:377-381.
56. Hsiao Y.L., Wu Y.S., Wu J.Y.W., Hsu M.H., Chen H.C., Lee S.Y., et al. Neuropsychological functions in patients with bipolar I and bipolar II disorder. Bipolar Disord 2009, 11:547-554.
57. Osher Y., Sela B.A., Levine J., Belmaker R.H. Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disord 2004, 6:82-86.
58. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002, 325:1202-1206.
59. Schafer J.H., Glass T.A., Bressler J., Todd A.C., Schwartz B.S. Blood lead is a predictor of homocysteine levels in a population-based study of older adults. Environ Health Perspect 2005, 113:31-35.
60. Guallar E., Silbergeld E.K., Navas-Acien A., Malhotra S., Astor B.C., Sharrett A.R., et al. Confounding of the relation between homocysteine and peripheral arterial disease by lead, cadmium and renal function. Am J Epidemiol 2006, 163:700-708.